BNP Paribas Financial Markets Has $549,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

BNP Paribas Financial Markets raised its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 50.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 275,946 shares of the biotechnology company’s stock after buying an additional 92,425 shares during the period. BNP Paribas Financial Markets’ holdings in Heron Therapeutics were worth $549,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Capital Investment Counsel Inc raised its stake in shares of Heron Therapeutics by 27.2% in the 2nd quarter. Capital Investment Counsel Inc now owns 14,625 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 3,125 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Heron Therapeutics by 15.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,922 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 3,991 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Heron Therapeutics by 16.0% in the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 6,328 shares during the period. nVerses Capital LLC acquired a new stake in shares of Heron Therapeutics in the second quarter worth $27,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Heron Therapeutics by 21.2% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock worth $90,000 after buying an additional 7,927 shares during the period. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

Shares of Heron Therapeutics stock opened at $1.60 on Friday. The company has a market cap of $243.36 million, a price-to-earnings ratio of -8.89 and a beta of 1.67. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.93. The company’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $2.28.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $32.81 million during the quarter, compared to analyst estimates of $36.40 million. During the same quarter in the prior year, the business earned ($0.17) earnings per share. As a group, research analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

HRTX has been the topic of several recent analyst reports. StockNews.com upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.